PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Nov 06, 2019

byncaipen

Ophthalmology

ProtoKinetix AAGP® Operational Update

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to provide the following updates regarding upcoming news in key areas. Current projects updates are expected from the...Read more

Aug 23, 2019

byncaipen

Ophthalmology

Tests Show AAGP® Preserved and Enabled Retinal Cells to Mature Without Compromise after 5-Month Milestone

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) updates shareholders regarding ongoing 3rd stage testing of retinal cell replacement therapy at the University of British Columbia. As previously reported, the...Read more

Jul 09, 2019

byncaipen

Ophthalmology

ProtoKinetix Reaches Mid-Point of 3rd Stage of Retinal Cell Replacement Therapy Testing at UBC

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has reached the mid-point of 3rd stage of testing in retinal cell replacement therapy at the University of British Columbia....Read more

Jun 07, 2019

byncaipen

Transplants

ProtoKinetix Achieves Primary Objective Safety at Midpoint of Clinical Trial

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) today announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP® PKX-001 treated islet cells used in conjunction...Read more

May 30, 2019

byncaipen

ProtoKinetix First in Series of Town Hall Shareholder Meetings

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) today announces that it will hold the first in a series of Town Hall Meetings. This meeting is being held...Read more

May 09, 2019

byncaipen

Transplants

Agreement Secured by ProtoKinetix to Start Heart Research Product Validation Studies

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is announcing that the Company has secured a partnership agreement with IMPART investigator team Canada at Dalhousie University and has...Read more

May 06, 2019

byncaipen

ProtoKinetix Discusses Investor Awareness Campaign and Recent Market Activity

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has been requested by OTC Markets Group to comment on certain recent promotional activity encouraging investors to purchase the Company’s...Read more

Apr 23, 2019

byncaipen

Ophthalmology

ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) updates it’s stockholders regarding phase 3 of testing using AAGP® in retinal cell replacement therapy at the University of British...Read more

Feb 26, 2019

byncaipen

Transplants

ProtoKinetix Releases Third in a Series of Scientific Update Videos

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the launch of the third in a series of informational videos by the Principal Investigators in each field currently...Read more

Jan 16, 2019

byncaipen

Ophthalmology

ProtoKinetix Releases Second in a Series of Scientific Update Videos

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX)announces the launch of the second in a series of informational videos by the Principal Investigators in each field currently being...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.